Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.34 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31112120 | 0.82 | CYP2C19 (0.33) | CYP2C19CYP2D6PRSS1CTSGCTRB1 | |
| SCHEMBL13967232 | 0.81 | KDM4E (0.37) | CYP2C19PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL16480859 | 0.80 | CYP2D6 (0.39) | CYP2C19CYP2D6PRSS1CTSGCTRB1 | |
| SCHEMBL4334873 | 0.79 | CYP2D6 (0.34) | CYP2C19CYP2D6MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL1097195 | 0.77 | NOS1 (0.31) | CYP2C19CYP2D6KDM4EGMNNUSP2 | |
| SCHEMBL4247208 | 0.77 | CYP2D6 (0.33) | CYP2C19CYP2D6PRSS1CTSGCTRB1 | |
| SCHEMBL8466979 | 0.76 | CYP2D6 (0.33) | CYP2C19CYP2D6ALDH1A1CYP2C9KMT2A | |
| SCHEMBL2040611 | 0.75 | — | — | |
| SCHEMBL9800469 | 0.75 | — | — | |
| SCHEMBL19851260 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | claimed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | claimed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | claimed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-10738041-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2020-08-11 | — | — | US | disclosed |
| US-10364239-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-07-30 | — | — | US | disclosed |
| US-20180319783-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2018-11-08 | — | — | US | disclosed |
| US-20180297991-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2018-10-18 | — | — | US | disclosed |
| EP-3364967-A2 | FERROPORTIN INHIBITORS | Vifor (International) AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| EP-3365339-A1 | NOVEL FERROPORTIN INHIBITORS | Vifor (International) AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068090-A1 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017068089-A2 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| EP-1844002-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006083924-A1 | 1-ACYLAMINO-2-HYDROXY-3-AMINO-W-ARYLALKANES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738041-B2 | Ferroportin inhibitors | SLC40A1, HAMP, TFRC | CYP2C19 1798/4885CYP2D6 1462/4885PRSS1 1583/4885 |
| US-20180297991-A1 | Novel Ferroportin Inhibitors | SLC40A1, HAMP, TFRC | CYP2C19 2391/4885CYP2D6 1833/4885PRSS1 1871/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | CYP2C19 101/4885CYP2D6 249/4885PRSS1 27/4885 |
| US-10364239-B2 | Ferroportin inhibitors | HAMP, SLC40A1, HMOX1 | CYP2C19 310/4885CYP2D6 276/4885PRSS1 2086/4885 |
| US-20180319783-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, FTH1 | CYP2C19 391/4885CYP2D6 307/4885PRSS1 2109/4885 |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | REN, AGTR1, AGTR2 | CYP2C19 318/4885CYP2D6 163/4885PRSS1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.